SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

11.34 -0.20 (-1.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about SELLAS Life Sciences Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Get insights into the top gainers and losers of Monday's pre-market session. ↗

September 14, 2026

Via Chartmill

SELLAS Stock Hits New Highs: What's Happening Today? ↗

June 26, 2026

SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are pushing higher Friday morning, extending Thursday’s strong rally.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 13, 2026

Via Chartmill

These stocks are moving in today's after hours session ↗

May 12, 2026

Via Chartmill

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗

January 09, 2026

Via Stocktwits

Why Is SELLAS Life Sciences Stock Falling Today? ↗

October 27, 2025

Via Stocktwits

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗

March 18, 2026

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

Via Stocktwits

SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗

March 12, 2026

The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.

Via Stocktwits

SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗

March 09, 2026

Shkreli argued that the company lacks a clear mechanism of action and strong clinical data.

Via Stocktwits

Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗

March 09, 2026

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

Via Stocktwits

Topics ETFs Government Stocks

SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗

March 09, 2026

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

Via Stocktwits

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗

March 06, 2026

The stock's recent surge has been driven by anticipation around the late-stage Regal trial evaluating its leukemia therapy Galinpepimut-S (GPS).

Via Stocktwits

SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗

March 05, 2026

Short interest has risen about 15% since the December update on the Phase 3 Regal trial.

Via Stocktwits

SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗

March 04, 2026

The rally comes ahead of results from the Phase 3 Regal trial testing Galinpepimut-S (GPS) as a maintenance treatment for AML patients.

Via Stocktwits

SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗

February 27, 2026

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage...

Via Stocktwits

Topics Death

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗

February 23, 2026

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

Via Stocktwits

Topics Regulatory Compliance

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗

January 14, 2026

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Via Stocktwits

Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗

January 06, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 06, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗

January 06, 2026

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Via Stocktwits

Topics Artificial Intelligence ETFs Stocks

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗

January 05, 2026

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

Via Stocktwits

Topics Death

Why Is SLS Stock Drawing Significant Investor Attention Today? ↗

December 31, 2025

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the...

Via Stocktwits

Topics Death

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗

December 29, 2025

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

Via Stocktwits

Topics Death

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗

December 24, 2025

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover.

Via Stocktwits

These stocks are gapping in today's session ↗

December 23, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗

December 17, 2025

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

Via Stocktwits

Topics Death

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗

December 08, 2025

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

Via Stocktwits

Topics Artificial Intelligence

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗

November 11, 2025

Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.